Zulresso (Brexanolone) for Depression

Overview
Zulresso is approved by the U.S. Food and Drug Administration (FDA) for the treatment of postpartum depression (PPD) in people 15 and older. As of July 2024, a person must participate in a restricted program called the Zulresso REMS (Risk Evaluation and Mitigation Strategy) to receive the drug, due to the risk of excessive sedation and sudden loss of consciousness. Zulresso is also known by its drug name, brexanolone.

Zulresso is a neuroactive steroid that works as a gamma-aminobutyric acid (GABA) A receptor positive modulator. It is thought to help regulate brain activity by enhancing the calming effects of GABA, a neurotransmitter, which may alleviate symptoms of PPD.

How do I take it?
Prescribing information states that Zulresso is administered as a continuous intravenous (IV) infusion over a 60-hour period in a health care setting. The medication must be diluted before administration and is given under continuous monitoring to ensure safety. Zulresso should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Zulresso include sedation or somnolence (drowsiness), dry mouth, loss of consciousness, and flushing or hot flush.

Rare but serious side effects may include excessive sedation, sudden loss of consciousness, and suicidal thoughts or behaviors. Individuals experiencing worsening symptoms or new thoughts of self-harm should inform their health care provider immediately.

For more information about this treatment, visit:

Label: Zulresso — Brexanolone Injection, Solution — DailyMed